For the year ending 2025-12-31, INBX had -$28,376K decrease in cash & cash equivalents over the period. -$129,825K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | -140,055 |
| Depreciation and amortization | 2,483 |
| Accretion of debt discount and non-cash interest expense | 2,439 |
| Stock-based compensation expense | 11,138 |
| Non-cash lease expense | 1,803 |
| Non-cash gain on transaction with acquirer | 0 |
| Loss on disposal of property and equipment | -12 |
| Accounts receivable | -200 |
| Other receivables | -20 |
| Receivables from related parties | -23 |
| Prepaid expenses and other current assets | -1,400 |
| Other non-current assets | 0 |
| Accounts payable | -3,301 |
| Accrued expenses | -4,361 |
| Operating lease liability | -1,595 |
| Net cash used in operating activities | -129,794 |
| Purchase of property and equipment | 31 |
| Proceeds from the sale of property and equipment | 3 |
| Net cash used in investing activities | -28 |
| Proceeds from the issuance of debt | 99,965 |
| Payment of third-party fees associated with debt | 125 |
| Proceeds from exercise of stock options | 1,606 |
| Net cash provided by financing activities | 101,446 |
| Net decrease in cash | -28,376 |
| Cash and cash equivalents at beginning of period | 152,596 |
| Cash and cash equivalents at end of period | 124,220 |
Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX)